{"id":562887,"date":"2021-09-13T18:54:01","date_gmt":"2021-09-13T18:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=562887"},"modified":"2021-09-13T18:54:01","modified_gmt":"2021-09-13T18:54:01","slug":"idiopathic-pulmonary-fibrosis-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_562887.html","title":{"rendered":"Idiopathic Pulmonary Fibrosis Market Analysis, Market Size & Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\n
\"Idiopathic<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Idiopathic Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Idiopathic Pulmonary Fibrosis – Market Insights, Epidemiology, and Market Forecast-2030”<\/strong>.<\/a><\/p>\n

DelveInsight’s “Idiopathic Pulmonary Fibrosis – Market Insights, Epidemiology, and Market Forecast-2030″<\/strong> <\/a>report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The total prevalent population of Idiopathic Pulmonary Fibrosis (IPF)  in the 7MM is expected to rise to 284,823 by 2030, during the study period [2017–2030]. <\/p>\n<\/li>\n

  2. \n

    The epidemiological data, presented by the National Institute of Health (NIH), estimated that IPF has a prevalence of 13 to 20 per 100,000 people worldwide. <\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. \n

      Idiopathic Pulmonary Fibrosis  market report covers a descriptive overview and comprehensive insight of the Idiopathic Pulmonary Fibrosis  epidemiology and Idiopathic Pulmonary Fibrosis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n<\/li>\n

    2. \n

      The Idiopathic Pulmonary Fibrosis market report provides insights on the current and emerging therapies.<\/p>\n<\/li>\n

    3. \n

      Idiopathic Pulmonary Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n

    4. \n

      The Idiopathic Pulmonary Fibrosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Idiopathic Pulmonary Fibrosis market.<\/p>\n<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Idiopathic Pulmonary Fibrosis Market Landscape.<\/a><\/strong><\/p>\n

      Idiopathic Pulmonary Fibrosis Overview<\/strong><\/p>\n

      Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs, associated with significant morbidity and poor prognosis. It is the most common form of fibrosing idiopathic interstitial pneumonia, is an inexorably progressive disease with a 5-year survival of ~20%.<\/p>\n

      The key players involved in the Idiopathic Pulmonary Fibrosis market:<\/strong><\/p>\n

        \n
      1. \n

        FibroGen, <\/p>\n<\/li>\n

      2. \n

        Kadmon Corporation, <\/p>\n<\/li>\n

      3. \n

        Promedior, <\/p>\n<\/li>\n

      4. \n

        Galapagos, <\/p>\n<\/li>\n

      5. \n

        MediciNova,<\/p>\n<\/li>\n

      6. \n

        And others.<\/p>\n<\/li>\n<\/ol>\n

        The launch of the emerging therapies is expected to significantly impact the Idiopathic Pulmonary Fibrosis treatment scenario in the upcoming years:-<\/strong><\/p>\n

        Drug covered<\/strong><\/p>\n

          \n
        1. \n

          Pamrevlumab, <\/p>\n<\/li>\n

        2. \n

          KD025, <\/p>\n<\/li>\n

        3. \n

          PRM-151, <\/p>\n<\/li>\n

        4. \n

          GLPG1690, <\/p>\n<\/li>\n

        5. \n

          Tipelukast,<\/p>\n<\/li>\n

        6. \n

          And others.<\/p>\n<\/li>\n<\/ol>\n

          Table of Contents<\/strong><\/p>\n

          1. Report Introduction<\/p>\n

          2. Executive Summary<\/p>\n

          3. SWOT analysis<\/p>\n

          4. Idiopathic Pulmonary Fibrosis  Patient Share (%) Overview at a Glance<\/p>\n

          5. Idiopathic Pulmonary Fibrosis  Market Overview at a Glance<\/p>\n

          6. Idiopathic Pulmonary Fibrosis  Disease Background and Overview<\/p>\n

          7. Idiopathic Pulmonary Fibrosis  Epidemiology and Patient Population<\/p>\n

          8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis <\/p>\n

          9. Idiopathic Pulmonary Fibrosis  Current Treatment and Medical Practices<\/p>\n

          10. Unmet Needs<\/p>\n

          11. Idiopathic Pulmonary Fibrosis  Emerging Therapies<\/p>\n

          12. Idiopathic Pulmonary Fibrosis  Market Outlook<\/p>\n

          13. Country-Wise Idiopathic Pulmonary Fibrosis  Market Analysis (2017–2030)<\/p>\n

          14. Market Access and Reimbursement of Therapies<\/p>\n

          15. Market drivers<\/p>\n

          16. Market barriers<\/p>\n

          17. Appendix<\/p>\n

          18. Idiopathic Pulmonary Fibrosis  Report Methodology<\/p>\n

          19. DelveInsight Capabilities<\/p>\n

          20. Disclaimer<\/p>\n

          21. About DelveInsight<\/p>\n

          Related Reports:<\/strong><\/p>\n

          Idiopathic Pulmonary Fibrosis Pipeline <\/a><\/strong><\/p>\n

          “Idiopathic Pulmonary Fibrosis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Idiopathic Pulmonary Fibrosis market. A detailed picture of the  Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and  Idiopathic Pulmonary Fibrosis treatment guidelines.<\/p>\n

          Idiopathic Pulmonary Fibrosis Epidemiology<\/a><\/strong><\/p>\n

          DelveInsight’s ‘Idiopathic Pulmonary Fibrosis  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Pulmonary Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           DelveInsight Business Research LLP<\/a>
          Contact Person:<\/strong> Kritika Rehani
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 9193216187
          Address:<\/strong>304 S. Jones Blvd #2432
          City:<\/strong> Las Vegas
          State:<\/strong> Nevada
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.delveinsight.com\/<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          DelveInsight Business Research LLP DelveInsight\u2019s \u2018Idiopathic Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-562887","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=562887"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562887\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=562887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=562887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=562887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}